Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Nears Target Goal For Voluntary Genomic Data Submissions

Executive Summary

FDA expects to reach its annual target of 20 submissions for the first time since the Voluntary Genomic Data Submission program began in 2005

You may also be interested in...

Comfort Level Rising With Voluntary Genomic Data Submission

Three years into FDA's Voluntary Genomic Data Submission program, companies are more comfortable with the agency's ability to separate the review of the voluntary data from regulatory actions, according to FDA Associate Director of Genomics Felix Freuh

Pharmacogenomics Guidance Cites Benefits Of Voluntary Submissions

FDA's final pharmacogenomics guidance outlines the benefits of voluntary pharmaceutical industry submissions of genomic data to the agency

FDA Genomics Guidance, Demographics Database To Improve Gender Analysis

Electronic clinical trial databases under development at FDA's Office of Women's Health will help sponsors design trials that account for gender and other demographic differences among patients, FDA Commissioner McClellan said




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts